Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 3/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578380 | 0.93 | PAK4 (0.52) | PAK4MKNK1TGFBR1ROCK2EGFR | |
| SCHEMBL3592877 | 0.92 | TGFBR1 (0.54) | PAK4MKNK1TGFBR1ROCK2EGFR | |
| SCHEMBL3578657 | 0.89 | TNIK (0.53) | PAK4TGFBR1ROCK2ABCG2NPC1 | |
| SCHEMBL3578585 | 0.86 | TGFBR1 (0.65) | TGFBR1ROCK2ABCG2ROCK1PDE5A | |
| SCHEMBL3584500 | 0.85 | PAK4 (0.51) | PAK4MKNK1TGFBR1ROCK2EGFR | |
| SCHEMBL3583464 | 0.85 | ROCK2 (0.58) | PAK4TGFBR1ROCK2EGFRABCG2 | |
| SCHEMBL3581577 | 0.83 | TGFBR1 (0.54) | PAK4MKNK1TGFBR1ROCK2ABCG2 | |
| SCHEMBL3587306 | 0.83 | ABCG2 (0.62) | ABCG2NOS1 | |
| SCHEMBL3588932 | 0.83 | ROCK2 (0.63) | TGFBR1ROCK2ABCG2ROCK1PDE5A | |
| SCHEMBL3577568 | 0.82 | ABCG2 (0.67) | TGFBR1ROCK2ABCG2ROCK1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | claimed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | claimed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1370553-A2 | RHO-KINASE INHIBITORS | Bayer Corporation (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | claimed |
| WO-2002076976-A2 | RHO-KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-03 | — | — | WO | claimed |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPHALAN | 2010-06-03 | — | — | US | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| WO-2008049000-A2 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20060142313-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2006-06-29 | — | — | US | disclosed |
| EP-1370553-B1 | RHO-KINASE INHIBITORS | BAYER AG (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1370553-A2 | RHO-KINASE INHIBITORS | Bayer Corporation (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | BAYER CORPORATION | 2003-07-03 | — | — | US | disclosed |
| WO-2002076976-A2 | RHO-KINASE INHIBITORS | BAYER CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142313-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | PAK4 178/4885MKNK1 244/4885TGFBR1 1599/4885 |
| US-20030125344-A1 | Preferrably (indazol-5-yl)-4-quinazolinamine derivatives; antitumor agents, treating erectile dysfunction, and coronary heart disease | CIT, PDE3A, PDE2A | PAK4 351/4885MKNK1 255/4885TGFBR1 1926/4885 |
| US-20100137324-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | PAK4 178/4885MKNK1 244/4885TGFBR1 1599/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | PAK4 414/4885MKNK1 596/4885TGFBR1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.